Author:
Niculescu-Duvaz Ion,Springer Caroline J.
Reference112 articles.
1. Bridgewater G, Springer CJ, Knox R, Minton N, Michael P, Collins M. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB 1954. Eur J Cancer. 1995; 31A: 2362–2370.
2. Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 1996; 56: 4735–4742.
3. Huber BE, Richards CA, Austin EA. VDEPT: An enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Adv Drug Del Rev. 1995; 17: 279–292.
4. Eaton JL, Perry MJA, Todryk SM, et al. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Ther. 2001; 8: 557–567.
5. Hermiston, T. Gene-delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Investig. 2000; 105: 1169–1172.